<?xml version="1.0" encoding="UTF-8"?>
<p id="p0150">Due to the high amount of cytokines produced by SARS-CoV (
 <xref rid="bib53" ref-type="bibr">He et al., 2006</xref>; 
 <xref rid="bib151" ref-type="bibr">Wong et al., 2004</xref>), MERS-CoV (
 <xref rid="bib35" ref-type="bibr">Falzarano et al., 2013</xref>; 
 <xref rid="bib36" ref-type="bibr">Faure et al., 2014</xref>), and SARS-CoV-2 (
 <xref rid="bib59" ref-type="bibr">Huang et al., 2020</xref>), corticosteroids are commonly used to treat patients with severe infection. However, studies involving corticosteroid-treated SARS and MERS patients show disrupted infection clearance and no effect on mortality (
 <xref rid="bib3" ref-type="bibr">Arabi et al., 2018</xref>; 
 <xref rid="bib133" ref-type="bibr">Stockman et al., 2006</xref>). It is prescribed that glucocorticoids are being used for a limited time (3–5 days), with a dosage not more than the equivalent of methylprednisolone 1–2 mg/kg/day for COVID-19 patients with severe illness, as a higher dose can prolong the coronavirus elimination due to immunomodulatory effects (
 <xref rid="bib26" ref-type="bibr">Commision, 2020</xref>). Therefore, corticosteroids should not be administered routinely. Ongoing clinical studies involving corticosteroid therapy in severely ill COVID-19 patients will help to understand the therapy's efficacy and safety.
</p>
